@daltonventure
以生命科学为根，向硬科技生长
It leverages cutting-edge synthetic-biology innovations to push everyday products like cosmetics toward safer, more sustainable formulations.
Those who walk deeper into the cycle always spot the next beam of light.
On December 11, 2025, **Datong Family company Astribot released LUMO-1, a next-generation embodied reasoning VLA model that successfully established a new paradigm for the robot "reasoning-action" closed loop**. Leveraging core technologies including a three-stage training architecture and structured reasoning, the model comprehensively outperformed mainstream baselines on critical tasks such as long-horizon multi-step manipulation and out-of-distribution generalization, enabling responses without programming.
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Bio-manufacturing: The "Next Decade" of the Global Industrial Landscape
On the afternoon of October 23, 2025, the "Sheng Yan Wan Wu | Bio-Manufacturing Industry Value Partners Conference," co-hosted by Dalton Venture and OPM Biosciences [688293], was held in Shanghai. Centered on the theme "Sheng Yan Wan Wu" (Life Begets All Things), the conference brought together representatives from government agencies, scholars from research institutes, industry-leading entrepreneurs, fund investors, and ecosystem partners to explore cutting-edge trends in bio-manufacturing and pathways for industrial collaboration.
The bio-manufacturing industry will undergo structural transformation around 2030.
In 2025, the global chronic pain treatment market will grow to 500 billion yuan.
AI is emerging as a new engine for breaking through in pain treatment
In September 2025, **Triastek, a Dalton Venture portfolio company, received the nation's first Pharmaceutical Manufacturing License for 3D-printed drug production issued by the Jiangsu Provincial Medical Products Administration**. This marks the first time that 3D printing pharmaceutical technology in China has achieved compliant, regulated manufacturing. It represents a critical step forward for Triastek in drug R&D and industrialization, as well as another milestone for Dalton Venture's investments in pharmaceutical innovation.
